TY - JOUR T1 - Guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps (CRSwNP) in Brazil JO - Brazilian Journal of Otorhinolaryngology (English Edition) T2 - AU - Anselmo-Lima,Wilma T. AU - Tamashiro,Edwin AU - Romano,Fabrizio R. AU - Miyake,Marcel M. AU - Roithmann,Renato AU - Kosugi,Eduardo M. AU - Nakanishi,Márcio AU - Fornazieri,Marco A. AU - Bezerra,Thiago F.P. AU - Mello,João F. AU - Lessa,Marcus M. AU - Voegels,Richard L. AU - Piltcher,Otávio B. AU - Sakano,Eulalia AU - Valera,Fabiana C.P. SN - 18088694 M3 - 10.1016/j.bjorl.2021.03.003 DO - 10.1016/j.bjorl.2021.03.003 UR - http://www.bjorl.org.br/en-guideline-for-use-immunobiologicals-in-articulo-S1808869421000628 AB - IntroductionSevere uncontrolled chronic rhinosinusitis with nasal polyps has a negative impact on an individual’s quality of life. Therefore, new biologics have emerged for use in specific phenotypes of chronic rhinosinusitis, changing the paradigms of its treatment. ObjectiveTo review the current status of biologic treatment indications in chronic rhinosinusitis. MethodsThe Brazilian Academy of Rhinology brought together different specialists to suggest a course of action, considering its particularities and aspects related to the national reality. ResultsOf particular interest for decision making will be the identification of subgroups of patients refractory to pre-existing treatment options and the construction of a strategy that improves their quality of life, with the best cost-benefit ratio. ConclusionThe use of biologics is a valid option for treatment in more severe cases. This strategy must be better understood and improved in the future, with more studies and greater clinical experience. ER -